Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

Inclusion Criteria: * 1\. Eighteen years or older on the day of consent * 2\. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component. * 3\. Patient must have progressed to at least one immune check point inhibitor-based therapy (antiPD1, anti-PDL1 o antiCTLA4) for the first line * 4\. Measurable disease per RECIST 1.1 as determined by the investigator * 5\. The subjects should not present disease that may be subsidiary of surgical treatment, radiotherapy or combined treatment with curative intent. * 6\. Recovery of toxicities related to any prior treatments to ≤ Grade 1 CTCAE v.4.03, unless adverse event(s) are clinically nonsignificant and/or stable on supportive therapy. * 7\. Eastern Cooperative Oncology Group Performance Status (PS) 0-2 * 8\. Adequately controlled blood pressure (BP) with or without antihypertensive medication to maintain a BP \<150/90 mmHg before the start of study treatment. * 9\. Adequate marrow function * Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 GI/L). * Platelets ≥ 100,000/mm3 (≥ 100 GI/L). * Hemoglobin ≥ 9 g/dL (≥ 5,6 mmol/L). * 10\. Adequate liver function * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 × ULN. * Total bilirubin ≤ 1.5 × upper limit of normal (ULN). * 11\. Adequate kidney function: calculated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockroft-Gault equation * 12\. Proteinuria \<2+ on urine test strip * 13\. Prothrombin Time (PT) or International Standard Ratio (INR) ≤ 1.2 x ULN. * 14\. Life expectancy \>3 months. * 15\. Patient able to ingest study drug and meet study follow-up requirements. * 16\. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception * 17\. Female subjects of childbearing potential must not be pregnant at screening. Exclusion Criteria: * 1\. Previous treatments with sunitinib are not permitted for the advanced or localized disease. * 2\. Major surgery within 3 weeks of patient inclusion * 3\. Radiation therapy or embolization within 2 weeks of first dose of sunitinib * 4\. Previous treatment with immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken prior to (3 months) patient inclusion * 5\. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue. * 6\. Current treatment on another clinical trial. * 7\. Treatment with known potent CYP3A4 inhibitors or inducers or that prolong the QT interval, within 7 days prior to the inclusion. * 8\. Prior radiation therapy to \>25% of the bone marrow. * 9\. Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. * 10\. Any gastrointestinal malabsorption disorder or any other condition that, in the opinion of the investigator, may affect the absorption of sunitinib or increase the risk of bleeding or perforation. * 11\. Presence of an unhealed wound or active ulcer. * 12\. Diarrhea grade III/IV in the screening period. * 13\. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. * 14\. Clinically significant cardio-cerebrovascular disease within 6 months prior to initiation of treatment. * 15\. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade that require treatment. * 16\. Corrected QT interval (QTc) interval \>500 msec. * 17\. Active hemoptysis within 6 weeks prior to initiation of study treatment. * 18\. Evidence of active bleeding or hemorrhagic diathesis. * 19\. Presence of endobronchial lesions and / or lesions that infiltrate large vessels. * 20\. Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). * 21\. Other clinically significant alterations: * Known human immunodeficiency virus (HIV) infection. * Presence of an uncontrolled active infection. * Presence of uncontrolled or symptomatic hypothyroidism. * Moderate-severe liver disease (Child Pugh B-C). * Requirement for hemodialysis or peritoneal dialysis. * History of solid organ transplantation. * 22\. Pregnancy or breastfeeding. * 23\. Any disease that, in the opinion of the investigator, interferes with the patient's ability to participate in the clinical trial.